Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03944421
Other study ID # NorthumbriaU001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 3, 2019
Est. completion date January 29, 2020

Study information

Verified date May 2019
Source Northumbria University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the effects of substituting red and processed meat in the diet with Quorn; a meat replacement product, on biomarkers of gut health. This will be a crossover design where participants will take part in 2 study periods where they will consume a diet containing red and processed meat during one of the study periods, whereas in the other study period, they will consume a diet containing Quorn.


Description:

There is a strong association between a diet which is high in red and processed meat, while low in fibre, and the incidence of colorectal cancer. This study aims to evaluate the effects of replacing red and processed meat in the diet with an alternative meat product such as Quorn, on biomarkers of gut health that may be associated with colorectal cancer.

Quorn is a product which has a considerable fibre component; thus, the replacement of red and processed meat with Quorn, will not only reduce the amount of compounds implicated to have deleterious effects in the gastrointestinal tract (E.G. haem, nitroso compounds, heterocyclic amines), but will also increase the delivery of fibre into the gastrointestinal system, that may well have an overall positive impact on gut health.

In this study, the participants will consume 240 grams (raw weight) of either red and processed meat, or Quorn each day for a 2 week period, this will be followed by a 4 week period where they will return to their usual dietary habits; before swapping to consume the alternative food (red/processed meat or Quorn) for another 2 week period.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date January 29, 2020
Est. primary completion date January 29, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Male

- 18-50 years.

- Not been diagnosed with colorectal cancer, or adenomas.

- Habitual omnivorous dietary pattern.

- BMI =18-30 kg/m2.

- Blood HbA1c <58mmol/mol (<6.5%) (not diagnosed with diabetes)

- Fasting total cholesterol<7.8 mmol/l

- Triglycerides <2.3 mmol/l

- Normal liver function (assessed by measuring liver enzymes in the screening blood sample).

- Blood pressure lower than BP <140/90 mmHg.

- Not suffering any cardiovascular diseases/ heart diseases e.g. stroke in the past 12 months.

- Do not suffer from chronic gastrointestinal problems (e.g. Inflammatory Bowel Disease, Irritable Bowel Syndrome, coeliac disease)

- Do not take supplements or medication that effects gastrointestinal health

- Not participated in a pre-/probiotic or laxative trial within the previous 3 months.

- Not been prescribed and/or taken antibiotics in the previous 6 months.

- No history of alcohol misuse based on self-reported alcohol intake and measurement of liver enzymes in the screening blood sample.

Exclusion Criteria:

- Been diagnosed with colorectal cancer and/or colorectal adenomas.

- Been diagnosed with gastrointestinal disorders (e.g. Inflammatory bowel disease, irritable bowel syndrome, coeliac disease)

- Adherence to a dietary pattern which excludes foods from an animal origin.

- Abnormal blood biochemistry based on standard clinical cut- offs, as well as blood markers not fitting the inclusion criteria set.

- Have history of food intolerances/allergies (e.g. gluten or dairy) or intolerances (e.g. lactose).

- Taking, or unwilling to stop taking anti-oxidant supplements (e.g. vitamin C, vitamin E, Multivitamin tablets, polyphenol supplements)

- Received antibiotics in the previous 6 months.

- Have participated in similar dietary or prebiotic/probiotics study in the previous 3 months.

- Current smoker.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Red and Processed Meat
Integration of 240 grams (raw weight) of red and processed meat into daily diet for 2 week period.
Quorn
Integration of 240 grams (uncooked weight) of Quorn into daily diet for 2 week period.

Locations

Country Name City State
United Kingdom Northumbria University Newcastle upon Tyne Tyne And Wear

Sponsors (2)

Lead Sponsor Collaborator
Northumbria University Quorn Foods

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Blood Cholesterol Changes in levels of cholesterol in blood samples 2 weeks
Other Blood Glucose Changes in levels of glucose in blood samples (HbA1c) 2 weeks
Primary Genotoxic potential of Faecal extracts from volunteers consuming intervention diets rich in red and processed meat versus diets containing Quorn Changes in the DNA damage causing capacity of aqueous stool extracts, assessed against HT29 and Caco-2 cells using the Comet assay. 2 weeks- Change from baseline following two week intervention with meat versus Quorn consumption
Secondary Oxidative Damage Changes in the concentration of 8-Hydroxyguanosine levels in urine samples. 2 weeks- Change from baseline following two week intervention with meat versus Quorn consumption
Secondary Endogenous Short Chain Fatty Acid Production Changes from baseline in the concentration of short chain fatty acids in stool samples, measures of propionate, acetate, butyrate valerate and isovalerate via Gas Chromatography. 2 weeks- Change from baseline following two week intervention with meat versus Quorn consumption
Secondary Gut Microbial Composition Evaluation of post-intervention changes in the composition of the stool microbiota composition from baseline samples. 2 weeks- Change from baseline following two week intervention with meat versus Quorn consumption
Secondary Endogenous Production of Para-Cresol Change in the concentration of the genotoxic metabolite para-cresol in urine samples 2 weeks- Change from baseline following two week intervention with meat versus Quorn consumption
Secondary Changes in MicroRNA Expression Evaluation of change in the abundance of microRNAs in plasma separated from blood samples following the intervention. 2 weeks- Change from baseline following two week intervention with meat versus Quorn consumption
See also
  Status Clinical Trial Phase
Suspended NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Not yet recruiting NCT05775146 - SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases Phase 2
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A